Regulatable gene expression systems for gene therapy applications: Progress and future challenges

Molecular Therapy

Volumn 12, Issue 2, 2005, Pages 189-211

  Goverdhana, S ^a   Puntel, M ^a   Xiong, W ^a   Zirger, J M ^a   Barcia, C ^a   Curtin, J F ^a   Soffer, E B ^a   Mondkar, S ^a   King, G D ^a   Hu, J ^a   Sciascia, S A ^a   Candolfi, M ^a   Greengold, D S ^a   Lowenstein, P R ^a   Castro, M G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CHLORAMPHENICOL ACETYLTRANSFERASE; DNA; DOXYCYCLINE; ECDYSONE RECEPTOR; ENOLASE; GANCICLOVIR; GLUTAMATE DECARBOXYLASE; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; LENTIVIRUS VECTOR; MACROGOL; MIFEPRISTONE; MINOCYCLINE; NEURITE PROMOTING FACTOR; PARVOVIRUS VECTOR; POLYETHYLENEIMINE; POLYLYSINE; PROGESTERONE RECEPTOR; PROTEIN P53; RECOMBINANT HUMAN INSULIN; RETROVIRUS VECTOR; STEROID RECEPTOR; TETRACYCLINE; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CANCER; CLINICAL TRIAL; CYTOTOXICITY; DIABETES MELLITUS; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; GENE EXPRESSION REGULATION; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; HEART MUSCLE ISCHEMIA; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LONG TERM CARE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARKINSON DISEASE; PHENOTYPE; REVIEW; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; TETRACYCLINE; TRANSDUCTION, GENETIC; TRANSGENES; VIRUSES;

EID: 22644442838     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.03.022     Document Type: Review

References (224)

1. J.M. Bergelson et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 275 1997 1320-1323
2. G.R. Nemerow and P.L. Stewart Role of alpha(v) integrins in adenovirus cell entry and gene delivery Microbiol. Mol. Biol. Rev. 63 1999 725-734
3. P.L. Leopold et al. Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells Hum. Gene Ther. 9 1998 367-378
4. N. Morral et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons Proc. Natl. Acad. Sci. USA 96 1999 12816-12821
5. P.R. Lowenstein and M.G. Castro Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences Gene Ther. 10 2003 946-954
6. P.R. Lowenstein and M.G. Castro Recent advances in the pharmacology of neurological gene therapy Curr. Opin. Pharmacol. 4 2004 91-97
7. M. Christ et al. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products Hum. Gene Ther. 11 2000 415-427
8. C.E. Thomas et al. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors Hum. Gene Ther. 12 2001 839-846
9. L. Grave et al. Differential influence of the E4 adenoviral genes on viral and cellular promoters J. Gene Med. 2 2000 433-443
10. H. Hu D. Serra and A. Amalfitano Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice Hum. Gene Ther. 10 1999 355-364
11. B.L. Hodges et al. Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications J. Virol. 75 2001 5913-5920
12. S. Kochanek et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase Proc. Natl. Acad. Sci. USA 93 1996 5731-5736
13. R.J. Parks et al. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal Proc. Natl. Acad. Sci. USA 93 1996 13565-13570
14. P. Ng et al. Development of a FLP/frt system for generating helper-dependent adenoviral vectors Mol. Ther. 3 5 Pt 1 2001 809-815
15. P. Umana Efficient et al. FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination Nat. Biotechnol. 19 2001 582-585
16. P.R. Lowenstein et al. High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into the brain Methods Enzymol. 346 2002 292-311
17. M. Grable and P. Hearing cis and trans requirements for the selective packaging of adenovirus type 5 DNA J. Virol. 66 1992 723-731
18. G. Schiedner et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat. Genet. 18 1998 180-183
19. M.A. Morsy et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene Proc. Natl. Acad. Sci. USA 95 1998 7866-7871
20. C.E. Thomas et al. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases Proc. Natl. Acad. Sci. USA 97 2000 7482-7487
21. W.K. O'Neal et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector Mol. Med. 6 2000 179-195
22. D. Maione et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus Proc. Natl. Acad. Sci. USA 98 2001 5986-5991
23. G. Toietta et al. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter Mol. Ther. 7 5 Pt 1 2003 649-658
24. P.L. Hermonat and N. Muzyczka Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells Proc. Natl. Acad. Sci. USA 81 1984 6466-6470
25. R.J. Samulski L.S. Chang and T. Shenk Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression J. Virol. 63 1989 3822-3828
26. X. Xiao J. Li and R.J. Samulski Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus J. Virol. 72 1998 2224-2232
27. H. Nakai T.A. Storm and M.A. Kay Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors Nat. Biotechnol. 18 2000 527-532
28. Z. Yan et al.Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy Proc. Natl. Acad. Sci. USA 97 2000 6716-6721
29. H.I. Ma et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector Gene Ther. 9 2002 2-11
30. C. Bordignon et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients Science 270 1995 470-475
31. D. Pannell and J. Ellis Silencing of gene expression: Implications for design of retrovirus vectors Rev. Med. Virol. 11 2001 205-217
32. C.E. Thomas A. Ehrhardt and M.A. Kay Progress and problems with the use of viral vectors for gene therapy Nat. Rev. Genet. 4 2003 346-358
33. Z. Li et al. Murine leukemia induced by retroviral gene marking Science 296 2002 497
34. B.J. Baum et al. Advances in vector-mediated gene transfer Immunol. Lett. 90 2003 145-149
35. J. Jakobsson et al. Targeted transgene expression in rat brain using lentiviral vectors J. Neurosci. Res. 73 2003 876-885
36. G. Trobridge and D.W. Russell Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors J. Virol. 78 2004 2327-2335
37. A. Blesch Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer Methods 33 2004 164-172
38. F. Carlotti et al. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes Mol. Ther. 9 2004 209-217
39. R. Vogel et al. A single lentivirus vector mediates doxycycline-regulated expression of transgenes in the brain Hum. Gene Ther. 15 2004 157-165
40. R. Zufferey et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J. Virol. 72 1998 9873-9880
41. T. Dull et al. A third-generation lentivirus vector with a conditional packaging system J. Virol. 72 1998 8463-8471
42. L. Naldini et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector Proc. Natl. Acad. Sci. USA 93 1996 11382-11388
43. + infected patients grouped according to CD4 count and viral load Mol. Ther. 9 2004 902-913
44. M. Kearns-Jonker et al. Use of lentiviral vectors to induce long-term tolerance to gal(+) heart grafts Transplantation. 77 2004 1748-1754
45. R. Whitley Herpes simplex viruses B. Fields D. Knipe P.M. Howley Eds. In Fields Virology 1996 Lippincott-Raven New York 2297-2342
46. J.C. Glorioso N.A. DeLuca and D.J. Fink Development and application of herpes simplex virus vectors for human gene therapy Annu. Rev. Microbiol. 49 1995 675-710
47. C.I. Ace et al. Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression J. Virol. 63 1989 2260-2269
48. N.A. DeLuca A.M. McCarthy and P.A. Schaffer Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4 J. Virol. 56 1985 558-570
49. D.Y. Ho et al. Herpes simplex virus vector system: Analysis of its in vivo and in vitro cytopathic effects J. Neurosci. Methods 57 1995 205-215
50. N. Wu et al. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22 J. Virol. 70 1996 6358-6369
51. P.L. Ward and B. Roizman Herpes simplex genes: The blueprint of a successful human pathogen Trends Genet. 10 1994 267-274
52. D.Y. Ho E.S. Mocarski and R.M. Sapolsky Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene Proc. Natl. Acad. Sci. USA 90 1993 3655-3659
53. M.J. During et al. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase Science 266 1994 1399-1403
54. M.G. Kaplitt et al. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector Proc. Natl. Acad. Sci. USA 91 1994 8979-8983
55. R.L. Smith et al. Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector J. Virol. 69 1995 4593-4599
56. M.J. Wood et al. Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors Gene Ther. 1 1994 283-291
57. J.A. Palmer et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system J. Virol. 74 2000 5604-5618
58. A.T. Dobson et al. A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons Neuron 5 1990 353-360
59. D.J. Fink et al. In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer Hum. Gene Ther. 3 1992 11-19
60. X.O. Breakefield Gene transfer into the nervous system using recombinant herpes virus vectors F. Gage Y. Christen Eds. In Gene Transfer and Therapy in the Nervous System 1992 Springer-Verlag Berlin 118-132
61. J.C. Glorioso et al. Development of herpes simplex virus as a gene transfer vector for central nervous system F. Gage Y. Christen Eds. In Gene Transfer and Therapy in the Nervous System 1992 Springer-Verlag Berlin 133-145
62. R.R. Spaete and N. Frenkel The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector Cell 30 1982 295-304
63. A.I. Geller and X.O. Breakefield A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons Science 241 1988 1667-1669
64. E.A. Burton D.J. Fink and J.C. Glorioso Gene delivery using herpes simplex virus vectors DNA Cell Biol. 21 2002 915-936
65. M.J. Wood et al. Immunological consequences of HSV-1-mediated gene transfer into the CNS Gene Ther. 1 Suppl. 1 1994 S82
66. S. Laquerre et al. Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells J. Virol. 72 1998 9683-9697
67. C.E. Lilley R.H. Branston and R.S. Coffin Herpes simplex virus vectors for the nervous system Curr. Gene Ther. 1 2001 339-358
68. H. Wakimoto et al. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells Gene Ther. 10 2003 983-990
69. U. Herrlinger et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector Gene Ther. 5 1998 809-819
70. J.M. Gillis Utrophin, a way to cure Duchenne muscle dystrophy Med. Sci. (Paris) 20 2004 442-447
71. M.T. da Cruz S. Simoes and M.C. de Lima Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons Exp. Neurol. 187 2004 65-75
72. E.J. Estruch et al. Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases J. Gene Med. 3 2001 488-497
73. R. Wang et al. Gene transfer of vascular endothelial growth factor plasmid/liposome complexes in glioma cells in vitro: The implication for the treatment of cerebral ischemic diseases Clin. Hemorheol. Microcirc. 23 2000 303-306
74. M. Hsiao et al. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival Biochem. Biophys. Res. Commun. 233 1997 359-364
75. J.A. Wolff Direct gene transfer into mouse muscle in vivo Science 247 4949 Pt 1 1990 1465-1468
76. B.E. Houk G. Hochhaus and J.A. Hughes Kinetic modeling of plasmid DNA degradation in rat plasma AAPS PharmSci. 1 1999 E9
77. R. Niven et al. Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice J. Pharm. Sci. 87 1998 1292-1299
78. R. Golan et al. DNA toroids: Stages in condensation Biochemistry 38 1999 14069-14076
79. D.D. Dunlap et al. Nanoscopic structure of DNA condensed for gene delivery Nucleic Acids Res. 25 1997 3095-3101
80. A.G. Schatzlein Non-viral vectors in cancer gene therapy: Principles and progress Anticancer Drugs 12 2001 275-304
81. M.A. Wolfert et al. Characterization of vectors for gene therapy formed by self-assembly of DNA with synthetic block co-polymers Hum. Gene Ther. 7 1996 2123-2133
82. S. Katayose and K. Kataoka Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer Bioconjugate Chem. 8 1997 702-707
83. S. Katayose and K. Kataoka Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-poly(L-lysine) block copolymer J. Pharm. Sci. 87 1998 160-163
84. V. Toncheva et al. Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers Biochim. Biophys. Acta. 1380 1998 354-368
85. Y.H. Choi et al. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier J. Controlled Release 54 1998 39-48
86. J.S. Kim et al. A new non-viral DNA delivery vector: The terplex system J. Controlled Release 53 1998 175-182
87. G.Y. Wu and C.H. Wu Receptor-mediated in vitro gene transformation by a soluble DNA carrier system J. Biol. Chem. 262 1987 4429-4432
88. C.H. Wu J.M. Wilson and G.Y. Wu Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo J. Biol. Chem. 264 1989 16985-16987
89. M. Cotten et al. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels Proc. Natl. Acad. Sci. USA 87 1990 4033-4037
90. J.L. Coll et al. In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer Gene Ther. 4 1997 156-161
91. R.I. Mahato et al. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine) Biochem. Pharmacol. 53 1997 887-895
92. I. Fajac et al. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells Hum. Gene Ther. 10 1999 395-406
93. A.G. Ziady et al. Ligand substitution of receptor targeted DNA complexes affects gene transfer into hepatoma cells Gene Ther. 5 1998 1685-1697
94. D.V. Schaffer and D.A. Lauffenburger Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery J. Biol. Chem. 273 1998 28004-28009
95. B. Xu et al. The contribution of poly-L-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation Gene Ther. 5 1998 1235-1243
96. S. Li et al. Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody Am. J. Physiol. Lung Cell Mol. Physiol. 278 2000 L504-L511
97. M.A. Zanta et al. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine Bioconjugate Chem. 8 1997 839-844
98. T. Bettinger J.S. Remy and P. Erbacher Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepatocytes Bioconjugate Chem. 10 1999 558-561
99. S.S. Diebold et al. Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection Hum. Gene Ther. 10 1999 775-786
100. R. Kircheis et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery Gene Ther. 4 1997 409-418
101. A.U. Bielinska et al. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo Biomaterials 21 2000 877-887
102. R.J. Mumper et al. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to muscle Pharm. Res. 13 1996 701-709
103. K.W. Leong et al. DNA-polycation nanospheres as non-viral gene delivery vehicles J. Controlled Release 53 1998 183-193
104. H. Isobe et al. Atomic force microscope studies on condensation of plasmid DNA with functionalized fullerenes Angew. Chem. Int. Ed. Engl. 40 2001 3364-3367
105. J.M. Benns et al. pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer Bioconjugate Chem. 11 2000 637-645
106. W. Guang Liu and K. De Yao Chitosan and its derivatives - a promising non-viral vector for gene transfection J. Controlled Release 83 2002 1-11
107. M. Gossen and H. Bujard Tight control of gene expression in mammalian cells by tetracycline-responsive promoters Proc. Natl. Acad. Sci. USA 89 1992 5547-5551
108. F.M. Wurm K.A. Gwinn and R.E. Kingston Inducible overproduction of the mouse c-myc protein in mammalian cells Proc. Natl. Acad. Sci. USA 83 1986 5414-5418
109. K.E. Mayo R. Warren and R.D. Palmiter The mouse metallothionein-I gene is transcriptionally regulated by cadmium following transfection into human or mouse cells Cell 29 1982 99-108
110. J. Ryals et al. A 46-nucleotide promoter segment from an IFN-alpha gene renders an unrelated promoter inducible by virus Cell 41 1985 497-507
111. N.E. Hynes and B. Groner Mammary tumor formation and hormonal control of mouse mammary tumor virus expression Curr. Top. Microbiol. Immunol. 101 1982 51-74
112. M.C. Hu and N. Davidson The inducible lac operator-repressor system is functional in mammalian cells Cell 48 1987 555-566
113. V.M. Rivera et al. A humanized system for pharmacologic control of gene expression Nat. Med. 2 1996 1028-1032
114. L. Di Croce et al. Steroid and nuclear receptors EMBO J. 18 1999 6201-6210
115. M.M. Burcin B.W. O'Malley and S.Y. Tsai A regulatory system for target gene expression Front. Biosci. 3 1998 c1-c7
116. E.S. Ngan et al. The mifepristone-inducible gene regulatory system in mouse models of disease and gene therapy Semin. Cell Dev. Biol. 13 2002 143-149
117. E.E. Baulieu Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor Science 245 1989 1351-1357
118. Y. Wang et al. A regulatory system for use in gene transfer Proc. Natl. Acad. Sci. USA 91 1994 8180-8184
119. M.M. Burcin et al. Adenovirus-mediated regulable target gene expression in vivo Proc. Natl. Acad. Sci. USA 96 1999 355-360
120. T.P. Yao et al. Functional ecdysone receptor is the product of EcR and Ultraspiracle genes Nature 366 1993 476-479
121. D. No T.P. Yao and R.M. Evans Ecdysone-inducible gene expression in mammalian cells and transgenic mice Proc. Natl. Acad. Sci. USA 93 1996 3346-3351
122. L.R. Karns et al. Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts BMC Biotechnol. 1 2001 11
123. D.C. Johns et al. Inducible genetic suppression of neuronal excitability J. Neurosci. 19 1999 1691-1697
124. M.B. Kumar et al. A single point mutation in ecdysone receptor leads to increased ligand specificity: Implications for gene switch applications Proc. Natl. Acad. Sci. USA 99 2002 14710-14715
125. D.E. Hallahan et al. Spatial and temporal control of gene therapy using ionizing radiation Nat. Med. 1 1995 786-791
126. S.A. Kaliberov L.N. Kaliberova and D.J. Buchsbaum Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas Gene Ther. 126 2004 407-417
127. S. Nuyts et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation Gene Ther. 8 2001 1197-1201
128. J. Worthington et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter Gene Ther. 7 2000 1126-1131
129. P. Chung et al. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism Nitric Oxide 8 2003 119-126
130. G. Gazit et al. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma Cancer Res. 59 1999 3100-3106
131. A. Ido et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter Cancer Res. 61 2001 3016-3021
132. M.I. Phillips et al. Vigilant vector: Heart-specific promoter in an adeno-associated virus vector for cardioprotection Hypertension 39 2 Pt 2 2002 651-655
133. H. Su et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts Proc. Natl. Acad. Sci. USA 101 2004 16280-16285
134. A. Auricchio et al. Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer Gene Ther. 9 2002 963-971
135. T. Alam and H.W. Sollinger Glucose-regulated insulin production in hepatocytes Transplantation 74 2002 1781-1787
136. R.Y. Pan et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model J. Virol. 73 1999 3410-3417
137. N. Perez et al. Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis Hum. Gene Ther. 13 2002 2161-2172
138. W. Hillen and C. Berens Mechanisms underlying expression of Tn10 encoded tetracycline resistance Annu. Rev. Microbiol. 48 1994 345-369
139. S. Urlinger et al. Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity Proc. Natl. Acad. Sci. USA 97 2000 7963-7968
140. H.J. Kim et al. Tetracycline repressor-regulated gene repression in recombinant human cytomegalovirus J. Virol. 69 1995 2565-2573
141. M. Gossen and H. Bujard Efficacy of tetracycline-controlled gene expression is influenced by cell type Biotechniques 19 1995 213-216
142. M. Molin et al. Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments J. Virol. 72 1998 8358-8361
143. V. Salucci et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system Gene Ther. 9 2002 1415-1421
144. J. Reiser et al. Development of multigene and regulated lentivirus vectors J. Virol. 74 2000 10589-10599
145. K.G. Rendahl et al. Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors Hum. Gene Ther. 13 2002 335-342
146. A. Chtarto et al. Tetracycline-inducible transgene expression mediated by a single AAV vector Gene Ther. 10 2003 84-94
147. N.S. Dejneka et al. Pharmacologically regulated gene expression in the retina following transduction with viral vectors Gene Ther. 8 2001 442-446
148. S. Lamartina et al. Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and nonhuman primates Mol. Ther. 7 2003 271-280
149. S. Lamartina et al. Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators Hum. Gene Ther. 13 2002 199-210
150. S. Goverdhana Regulatable transgene expression from gutless adenoviral vectors In Molecular Therapy Abstracts The American Society of Gene Therapy 7th Annual Meeting, Minneapolis 2004
151. S. Freundlieb C. Schirra-Muller and H. Bujard A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells J. Gene Med. 1 1999 4-12
152. J. Flint and T. Shenk Viral transactivating proteins Annu. Rev. Genet. 31 1997 177-212
153. T.C. Harding et al. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system Nat. Biotechnol. 16 1998 553-555
154. O. Corti et al. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors Nat. Biotechnol. 17 1999 349-354
155. O. Corti et al. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease Proc. Natl. Acad. Sci. USA 96 1999 12120-12125
156. J.R. Smith-Arica et al. Cell-type-specific and regulatable transgenesis in the adult brain: Adenovirus-encoded combined transcriptional targeting and inducible transgene expression Mol. Ther. 2 2000 579-587
157. T.C. Harding et al. Tetracycline-regulated transgene expression in hippocampal neurones following transfection with adenoviral vectors J. Neurochem. 69 1997 2620-2623
158. C.A. Gerdes M.G. Castro and P.R. Lowenstein Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo Mol. Ther. 2 2000 330-338
159. R.A. Dewey et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials Nat. Med. 5 1999 1256-1263
160. J.R. Smith-Arica et al. Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo Endocrinology 142 2001 2521-2532
161. T.D. Southgate et al. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries Endocrinology 141 2000 3493-3505
162. M.G. Castro et al. Cell-type specific expression in the pituitary: physiology and gene therapy Biochem. Soc. Trans. 27 1999 858-863
163. J.C. Williams et al. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas Mol. Ther. 4 2001 593-602
164. J.D. Silvertown B.J. Geddes and A.J. Summerlee Adenovirus-mediated expression of human prorelaxin promotes the invasive potential of canine mammary cancer cells Endocrinology 144 2003 3683-3691
165. J. Balsinde M.A. Balboa and E.A. Dennis Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2 Proc. Natl. Acad. Sci. USA 95 1998 7951-7956
166. M. Murakami et al. Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways J. Biol. Chem. 274 1999 3103-3115
167. C.E. Hack et al. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells Immunol. Today. 18 1997 111-115
168. U.J. Tietge et al. A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver J. Gene Med. 5 2003 567-575
169. J. Bennett et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina Invest. Ophthalmol. Visual Sci. 35 1994 2535-2542
170. T. Li et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector Invest. Ophthalmol. Visual Sci. 35 1994 2543-2549
171. H. Wenkel and J.W. Streilein Analysis of immune deviation elicited by antigens injected into the subretinal space Invest. Ophthalmol. Visual Sci. 39 1998 1823-1834
172. A. Block et al. Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors Anticancer Res. 22 2002 3285-3292
173. H. Tahara et al. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts Hum. Gene Ther. 6 1995 1607-1624
174. M. Caruso et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc. Natl. Acad. Sci. USA 93 1996 11302-11306
175. A. Block et al. Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system J. Gene Med. 5 2003 190-200
176. A. Hurtado-Lorenzo et al. Use of recombinant adenovirus for gene transfer into the rat brain: Evaluation of gene transfer efficiency, toxicity, and inflammatory and immune reactions Methods Mol. Med. 76 2003 113-133
177. P.R. Lowenstein et al. Nonneurotropic adenovirus: A vector for gene transfer to the brain and gene therapy of neurological disorders Int. Rev. Neurobiol. 55 2003 3-64
178. N.A. Do Thi Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease Gene Ther. 11 2004 746-756
179. D.A. Kozlowski et al. Quantitative analysis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harboring glial cell line-derived neurotrophic factor into the primate caudate nucleus Mol. Ther. 3 2001 256-261
180. D.L. Choi-Lundberg et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy Science 275 1997 838-841
181. D.L. Choi-Lundberg et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor Exp. Neurol. 154 1998 261-275
182. H. Kojima et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain Biochem. Biophys. Res. Commun. 238 1997 569-573
183. C.E. Thomas et al. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain Mol. Ther. 3 2001 36-46
184. P. Chenuaud et al. Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle Mol. Ther. 9 2004 410-418
185. W. Xiong et al. Tightly regulated helper-dependent adenoviral-mediated transgene expression in vitro and in vivo In Society for Neuroscience, 34th Annual Meeting, October 23-27, 2004 2004 San Diego, CA
186. C.E. Thomas et al. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain Mol. Ther. 3 2001 36-46
187. J.E. Lisman Proc. Natl. Acad. Sci. USA 82 1985 3055-3057
188. G. Hedou and I.M. Mansuy Inducible molecular switches for the study of long-term potentiation. Philos Trans. R. Soc. London B Biol. Sci. 358 2003 797-804
189. A. Iida et al. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system J. Virol. 70 1996 6054-6059
190. J.J. Hwang Z. Scuric and W.F. Anderson Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system J. Virol. 70 1996 8138-8141
191. P.A. Kenny T. Enver and A. Ashworth Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line BMC Mol. Biol. 3 2002 13
192. A. Hofmann G.P. Nolan and H.M. Blau Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette Proc. Natl. Acad. Sci. USA 93 1996 5185-5190
193. L. Naldini et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263-267
194. T. Kafri et al. Lentiviral vectors: Regulated gene expression Mol. Ther. 1 2000 516-521
195. J. Johansen et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS Gene Ther. 9 2002 1291-1301
196. E. Regulier et al. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease Hum. Gene Ther. 13 2002 1981-1990
197. M.S. Brenz et al. Verca Cocaine-induced expression of the tetraspanin CD81 and its relation to hypothalamic function Mol. Cell. Neurosci. 17 2001 303-316
198. A. Bahi et al. CD81-induced behavioural changes during chronic cocaine administration: In vivo gene delivery with regulatable lentivirus Eur. J. Neurosci. 19 2004 1621-1633
199. L.H. McGee Sanftner et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina Mol. Ther. 3 5 Pt 1 2001 688-696
200. G. Chen et al. Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy Proc. Natl. Acad. Sci. USA 93 1996 14795-14799
201. J. Wilsey et al. Hypothalamic delivery of doxycycline-inducible leptin gene allows for reversible transgene expression and physiological responses Gene Ther. 9 2002 1492-1499
202. G.L. Gallia and K. Khalili Evaluation of an autoregulatory tetracycline regulated system Oncogene 16 1998 1879-1884
203. C.A. Strathdee M.R. McLeod and J.R. Hall Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector Gene. 229 1999 21-29
204. S. Folliot et al. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector J. Gene Med. 5 2003 493-501
205. L. Jiang et al. Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR Gene Ther. 11 2004 1057-1067
206. J. Johnston et al. Regulated expression of erythropoietin from an AAV vector safely improves the anemia of β-thalassemia in a mouse model Mol. Ther. 7 2003 493-497
207. F. Apparailly et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: Application to experimental arthritis Hum. Gene Ther. 13 2002 1179-1188
208. D.G. Brockstedt et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration Clin. Immunol. 92 1999 67-75
209. L. Cordier et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies Hum. Gene Ther. 12 2001 205-215
210. D. Favre et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus J. Virol. 76 2002 11605-11611
211. M.E. Fotaki J.R. Pink and J. Mous Tetracycline-responsive gene expression in mouse brain after amplicon-mediated gene transfer Gene Ther. 4 1997 901-908
212. D.Y. Ho J.R. McLaughlin and R.M. Sapolsky Title Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system Brain Res. Mol. Brain Res. 41 1996 200-209
213. F. Schmeisser M. Donohue and J.P. Weir Tetracycline-regulated gene expression in replication-incompetent herpes simplex virus vectors Hum. Gene Ther. 13 2002 2113-2124
214. U. Herrlinger et al. HSV-1 infected cell proteins influence tetracycline-regulated transgene expression J. Gene Med. 2 2000 379-389
215. B. Staff First clinical trial for Parkinson's gene therapy gets approval 2002
216. I.M. Germano et al. Adenovirus/herpes simplex-thymidine kinase/ ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas J. Neurooncol. 65 2003 279-289
217. M.D. Prados et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial J. Neurooncol. 65 2003 269-278
218. F.F. Lang et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results J. Clin. Oncol. 21 2003 2508-2518
219. H. Ren et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki Forest virus vector carrying the human interleukin-12 gene - a phase I/II clinical protocol J. Neurooncol. 64 2003 147-154
220. M.J. During et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation Hum. Gene Ther. 12 2001 1589-1591
221. A.J. Mundt et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities Clin. Cancer Res. 10 2004 5747-5753
222. N. Senzer et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors J. Clin. Oncol. 22 2004 592-601
223. Y. Tang et al. Vigilant vectors: Adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases Methods 28 2002 259-266
224. J.E. Donello J.E. Loeb and T.J. Hope Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element J. Virol. 72 1998 5085-5092